GlassScriptPhysician profile
W Bryan Sims
NPI 1700822780
$11,551.79
in general payments reported to CMS, 2019-2025
40 companies · $2,217 in 2025
The $2,217 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,643 · 2022: $2,374 · 2023: $3,105 · 2024: $2,212 · 2025: $2,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,534.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,271.35 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,336.56 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,089.01 | 2021-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $963.75 | 2021-2024 | Xarelto, Spravato |
| Lilly USA, LLC | $738.86 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $642.78 | 2021-2025 | Ozempic, Rybelsus |
| Nevro Corp. | $600.36 | 2022-2023 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.51 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $275.25 | 2022-2025 | |
| Corcept Therapeutics | $269.47 | 2021-2025 | Korlym |
| Axsome Therapeutics, INC. | $266.79 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $257.76 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Phathom Pharmaceuticals, INC. | $249.98 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $163.10 | 2022 | |
| Althera Pharmaceuticals LLC | $151.84 | 2021-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $147.49 | 2023 | Freestyle Libre 3 |
| Stryker Corporation | $146.20 | 2025 | Mako |
| Merck Sharp & Dohme LLC | $137.80 | 2021-2024 | Gardasil 9, Gardasil |
| Halozyme INC | $125.00 | 2023 | |
| Astellas Pharma US INC | $124.99 | 2023 | Veozah |
| Edwards Lifesciences Corporation | $124.99 | 2023 | Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2023 | Uptravi, Opsumit |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Pfizer INC. | $123.70 | 2021-2025 | |
| Dexcom, INC. | $121.78 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $117.40 | 2021-2024 | |
| Exact Sciences Corporation | $86.51 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $68.83 | 2021-2022 | |
| Sanofi Pasteur INC. | $61.83 | 2021 | |
| Gilead Sciences, INC. | $47.30 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $34.82 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $33.31 | 2021-2022 | |
| Janssen Biotech, INC. | $32.98 | 2024 | Tremfya |
| Esperion Therapeutics, INC. | $30.54 | 2024-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.93 | 2021-2022 | |
| Scpharmaceuticals INC. | $22.30 | 2025 | |
| Organon LLC | $22.16 | 2022-2023 | Nexplanon |
| Alk-Abello, INC | $18.09 | 2024 | Odactra, Ragwitek, Grastek |
| Viatris Specialty LLC | $16.90 | 2025 | Yupelri |
| Biogen, INC. | $15.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw W Bryan Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.